Wantai Biotech announced that its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. has received the “Notice of Acceptance”, an administrative licensing document from the State Drug Administration, and the clinical trial application for the “recombinant respiratory syncytial virus vaccine” declared by the company has been accepted.

Wantai Biotech announced that its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. has received the “Notice of Acceptance”, an administrative licensing document from the State Drug Administration, and the clinical trial application for the “recombinant respiratory syncytial virus vaccine” declared by the company has been accepted.